Navigation Sciences – Real-Time Margin Measurement for Precision Cancer Surgery

Real-Time Margin Measurement

for Precision Cancer Surgery

Addressing Unmet Needs in Soft Tissue Surgery

Navigation Sciences is developing the NaviSci™ system to address the growing need to locate and remove lung and other soft tissue cancers.

Real-time GPS
Navigation

Precise Margin
Control

Minimally
Invasive

The NaviSci System, currently in clinical development, has great potential to:

Reduce early-stage cancer recurrence risk
Conserve lung function
Improve surgical workflow
Shorten hospital length of stay

NaviSci’s first application is in early-stage lung cancer, where there are more than 76,000 new cases each year in the U.S.; the number is growing annually due to increasing adoption of CT x-ray screening.

Overall, there are approximately 450,000 soft tissue cancer diagnoses annually in the U.S. where NaviSci has potential application.

Addressable U.S. market opportunity Infographic

Navigation Sciences initiates clinical feasibility study of the NaviSci™ System.

04/21 |

Navigation Sciences initiates clinical feasibility study of the NaviSci™ System. Read more

Navigation Sciences receives approval from MassGeneral Brigham IRB to begin first in human clinical trial of NaviSci System.

02/21 |

Navigation Sciences receives approval from MassGeneral Brigham IRB to begin first in human clinical trial of NaviSci System. Read more

Navigation Sciences completes oversubscribed, $2.4 million Series A financing.

11/20 |

Navigation Sciences completes oversubscribed, $2.4 million Series A financing. Read more

FDA clears Navigation Sciences IDE for first clinical trial.

08/20 |

FDA clears Navigation Sciences IDE for first clinical trial. Read more

Navigation Sciences raises $1.5 million seed round.

05/20 |

Navigation Sciences raises $1.5 million seed round. Read more

Navigation Sciences acquires exclusive rights to novel technology for minimally invasive lung cancer, and other soft tissue procedures.

11/18 |

Navigation Sciences acquires exclusive rights to novel technology for minimally invasive lung cancer, and other soft tissue procedures. Read more

Download Navigation Sciences Executive Summary

NaviSci is based on technology developed by the company’s co-founders, leaders in thoracic surgery and advanced surgical navigation technology, Raphael Bueno, M.D., Chief, Thoracic Surgery, and Jayender Jagadeesan, Ph.D., Associate Professor of Radiology both at Brigham & Women’s Hospital and Harvard Medical School. View our leadership team

Home